Curriculum Vitae

PERSONAL INFORMATION Martin Bauer

WORK EXPERIENCE

December 2004-January 2005 Research associate Medical University of Vienna, Department of Clinical (Austria) Phase I and II studies Pharmacokinetics PET/MR Imaging studies Assessing target tissue penetration with Positron Emission Tomography and Microdialysis DDIs

July 2017- Present Senior Consultant Medical University of Vienna, Department of Psychiatry and Psychotherapy (Austria) Outpatients clinic, psychiatric intermediate care unit, emergency psychiatry, memory clinic, Phase II-IV studies

March 2011- Present Registered Consultant in Clinical Pharmacology Medical University of Vienna/Vienna General Hospital (Austria) Clinacal pharmacology outpatient clinics, DDIs, pharmacokinetics, microdialysis, PET/MR imaging of ABC transporters, Phase I-II studies

March 2014- Present Registered Consultant in Psychiatry Medical University of Vienna/Vienna General Hospital (Austria) General psychiatry, Schizophrenia, affective disorders, dementia, child and adolescent psychiatry

March 2015- Present Ethics committee member Medical University of Vienna/Vienna General Hospital (Austria) Reviewing projects, discussion

July 2016- Present Associate Professor of Clinical Pharmacology Medical University of Vienna/Vienna General Hospital (Austria) Teaching, provide training, Senior Principal Investigator Clinical Research Phase I-II studies, DDIs, pharmacokinetics, bioequivalence, microdialysis, PET/MR imaging of ABC transporters EDUCATION AND TRAINING

January 2005-March 2014 Clinical training (Psychiatry, Clinical Pharmacology) Medical University of Vienna/Vienna General Hospital (Austria)

August 2006-August 2006 EudraVigilance User Training Certificate EMEA (United Kingdom) Pharmacovigilance January 2015-October 2015 Research Fellow University of Manchester (United Kingdom) Neuroinflammation and Neurooncology. Preclinical and clinical imaging. ADDITIONAL INFORMATION

Expertise Clinical Pharmacology, Target Tissue Pharmacokinetics, Pharmacokinetics,

12/02/2021 European Medicines Agency Page 1/6 Psychiatry, Schizophrenia, Depression, Development, Phase I, Phase II, Blood-Brain Barrier, Drug Transporters, Positron Emission Tomography, Microdosing. Train patient rappresentatives Publications Peer-Reviewed Original Articles 2005-2020 Cumulative impact factor: 277 (125 as first, senior or corresponding author) (* corresponding author, # contributed equally, IF= impact factor) 1.A Weidenauer#, M Bauer#, U Sauerzopf, L Bartova, N Lukas, S Pfaff, C Philippe, N Berroterán-Infante, V Pichler, B Meyer, U Rabl, P Sezen, P Cumming, T Stimpfl, H Sitte, R Lanzenberger, N Mossaheb, A Zimprich, P Rusjan, G Dorffner, M Mitterhauser, M Hacker, L Pezawas, S Kasper, W Wadsak, N Praschak-Rieder, M Willeit. On the relationship of first-episode psychosis to the am-phetamine-sensitized state: A dopamine D2/3 receptor agonist radioligand study. Translational Psychiatry (2020) 10:2 https://doi.org/10.1038/s41398-019-0681-5 IF 2017 5.182 2.N Hommer, M Kallab, S Szegedi, S Puchner, K Stjepanek, M Bauer, R Werkmeister, L Schmetterer, M Abensperg-Traun, G Garhofer, D Schmidl. The effect of orally administered on optic nerve head blood flow in healthy subjects- a randomized . Clin Pharmacol Ther (2020) 108(1):155-161. doi: 10.1002/cpt.1797 IF 2017 6.544 3.I Hernández Lozano, M Bauer, B Wulkersdorfer, A Traxl, C Philippe, M Weber, S Häusler, B Stieger, U Jäger, S Mairinger, T Wanek, M Hacker, M Zeitlinger, O Langer. Measurement of hepatic ABCB1 and ABCG2 transport activity with [11C]tariquidar and PET in humans and mice. Mol Pharmaceut (2019) [accepted on 02.12.2019] IF 2017 4.556 4.B Wulkersdorfer, M Bauer, R Karch, H Stefanits, C Philippe, M Weber, T Czech, M-C Menet, X Declèves, JA Hainfellner, M Preusser, M Hacker, M Zeitlinger, M Müller, O Langer. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast enhancing brain tumors with positron emission tomography. EJNMMI Research (2019) [accepted on 01.12.2019] IF 2017 2.630 5.V Zoufal, S Mairinger, M Brackhan, M Krohn, T Filip, M Sauberer, J Stanek, T Wanek, N Tournier, M Bauer, J Pahnke, O Langer. Imaging P-glycoprotein Induction at the Blood-Brain Barrier of a Beta-Amyloidosis Mouse Model with 11C-Metoclopramide PET. J Nucl Med (2019) [accepted on 18.10.2019] IF 2017 7.439 6.LKS Sundar, O Muzik, L Rischka, A Hahn, R Lanzenberger, M Hienert, E-M Klebermass, M Bauer, I Rausch, E Pataraia, T Traub-Weidinger and T Beyer. The promise of fully-integrated PET/MR imaging: Non-invasive clinical quantification of cerebral glucose metabolism. J Nucl Med (2019) [accepted on 15.07.2019] IF 2017 7.439 7.V Touzeau, M Skoll, P Tajpara, P Kienzl, A Wesinger, S Saluzzo, M Bauer, MC Aichelburg, C Bangert, W Bauer, G Stingl, A Rieger, K Grabmeier-Pfistershammer, C Schuster. Preva-lence of skin-specific autoantibodies in HIV-infected patients and uninfected controls. Acta Dermato-Venereologica (2019) 99(11):978-983. doi: 10.2340/00015555-3251 IF 2017 3.000 8.I Hernández Lozano, R Karch, M Bauer, M Blaickner, A Matsuda, B Wulkersdorfer, M Ha-cker, M Zeitlinger, O Langer. Towards improved pharmacokinetic models for the analysis of transporter-mediated hepatic disposition of drug molecules with positron emission tomogra-phy. AAPS Journal (2019) 21(4):61. doi: 10.1208/s12248-019-0323-0 IF 2017 3.804 9.M Bauer, N Tournier, O Langer. Imaging P-glycoprotein function at the blood-brain barrier as a determinant of the variability in response to CNS . Clin Pharmacol Ther (2019) 105(5):1061-1064. doi: 10.1002/cpt.1402. IF 2017 6.544 10.A Traxl, S Mairinger, T Filip, M Sauberer, J Stanek, S Poschner, W Jäger, V Zoufal, G Novarino, N Tournier, M Bauer, T Wanek, O Langer. Inhibition of ABCB1 and ABCG2 at the mouse blood-brain barrier with marketed drugs to improve brain delivery of the model ABCB1/ABCG2 substrate [11C]erlotinib. Mol Pharmaceut (2019) 16 (3),12821293 doi:

12/02/2021 European Medicines Agency Page 2/6 10.1021/acs.molpharmaceut.8b01217 IF 2017 4.556 11.N Tournier#, M Bauer#*, V Pichler, L Nics, E-M Klebermass, K Bamminger, S Poschner, P Matzneller, M Weber, F Caillé, S Auvity, S Marie, W Jäger, W Wadsak, Marcus Hacker, M Zeitlinger, O Langer. Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Sub-strate 11C-Metoclopramide Assessed with PET Imaging in Humans. J Nucl Med (2019) 60(7):985-991. doi: 10.2967/jnumed.118.219972 IF 2017 7.439 12.M Bauer, R Karch, B Wulkersdorfer, C Philippe, L Nics, E-M Klebermass, M Weber, S Poschner, H Haslacher, W Jäger, N Tournier, W Wadsak, M Hacker, M Zeitlinger, O Langer. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier. J Nucl Med. (2019) 60:486-491. doi: 10.2967/jnumed.118.216432 IF 2017 7.439 13.M Bauer, A Traxl, A Matsuda, R Karch, C Philippe, L Nics, EM Klebermass, B Wulkersdorfer, M Weber, S Poschner, N Tournier, W Jäger, W Wadsak, M Hacker, T Wanek, M Zeitlinger, O Langer. Effect of rifampicin on the distribution of [11C]erlotinib to the liver, a translational PET study in humans and in mice. Mol Pharm (2018) 1;15(10):4589-4598. doi: 10.1021/acs.molpharmaceut.8b00588. IF 2017 4.556 14.D Amor, S Goutal, S Marie, F Caillé, M Bauer, O Langer, S Auvity, N Tournier. Impact of rifampicin-inhibitable transport on the liver distribution and tissue kinetics of erlotinib as-sessed with PET imaging in rats. EJNMMI Research (2018) 16;8(1):81 IF 2017 2.630 15.S Auvity, F Caillé, S Marie, C Wimberley, M Bauer, O Langer, I Buvat, S Goutal, N Tournier. P-glycoprotein (ABCB1) inhibits the influx and increases the efflux of 11C-metoclopramide across the blood-brain barrier: a PET study on non-human primates. J Nucl Med (2018). 59(10):1609-1615. doi: 10.2967/jnumed.118.210104. IF 2017 7.439 16.C Schuster, FJ Mayer, C Wohlfahrt, R Marculescu, M Skoll, R Strassl, N Pavo, T Popow-Kraupp, M Hülsmann, M Bauer, MC Aichelburg, A Rieger, G Goliasch. Acute HIV infection results in sub-clinical inflammatory cardiomyopathy. J Infect Dis (2018) 2;218(3):466-470 doi: 10.1093/infdis/jiy183 IF 2017 5.186 17.P Matzneller, M Kussmann, S Eberl, A Maier-Salamon, W Jäger, M Bauer, O Langer, M Zeitlinger, W Poeppl. Pharmacokinetics of the P-gp inhibitor tariquidar in rats after intravenous, oral and intraperitoneal administration. Eur J Drug Metab Pharmacokinet (2018) 43(5):599-606 doi: 10.1007/s13318-018-0474-x. IF 2017 1.362 18.A Chaney, M Bauer#, D Bochicchio#, A Semigova, M Kassiou, KE Davies, SR Williams, H Boutin Longitudinal investigation of neuroinflammation and metabolite profiles in the APPswe×PS1e9 transgenic mouse model of Alzheimers disease. J Neurochem (2018) 144(3):318-335. doi: 10.1111/jnc.14251 IF 2017 4.609 19.M Bauer, A Matsuda, B Wulkersdorfer, C Philippe, A Traxl, C Özvegy-Laczka, J Stanek, L Nics, EM Klebermass, S Poschner, W Jäger, I Patik, E Bakos, G Szakács, W Wadsak, M Hacker, M Zeitlinger, O Langer. Influence of OATPs on hepatic disposition of erlotinib measured with positron emission tomography. Clin Pharmacol Ther (2018) 104(1):139-147. doi: 10.1002/cpt.888 IF 2017 6.544 20.ML Lassen, O Mutzik, T Beyer, M Hacker, CN Ladefoged, J Cal Gonzalez, W Wadsak, I Rausch, M Zeitlinger, O Langer, M Bauer*. Reproducibility of Quantitative Brain Imaging Using a PET-only and a Combined PET/MR System. Front Neurosci (2017) 11:396 doi: 10.3389/fnins.2017.00396. eCollection 2017. IF 2017 3.877 21.M Bauer, B Wulkersdorfer, R Karch, C Philippe, W Jäger, W Wadsak, M Hacker, M Zeitlin-ger, O Langer. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[11C] in elderly versus young subjects. Br J Clin Pharmacol. (2017) 83(9):1991-9 doi: 10.1111/bcp.13301 IF 2017 3.838 22.A Matsuda, R Karch, M Bauer, A Traxl, M Zeitlinger, O Langer. A Prediction Method for P-glycoprotein-Mediated Drug-Drug Interactions at the Human Blood-Brain Barrier from Blood Concentration-Time Profiles, Validated with PET Data. J Pharm Sci. (2017) 106(9):2780-6 doi: 10.1016/j.xphs.2017.03.024 IF 2017 2.575 23.M Bauer, R Karch, N Tournier, S Cisternino, W Wadsak, M Hacker, P Marhofer, M Zeitlinger, O Langer. Assessment of P-glycoprotein Transport Activity at the Human BloodRetinal Barrier with (R)11C-verapamil PET. J Nucl Med (2017) 58(4):678-681 doi: 10.2967/jnumed.116.182147 IF 2017 7.439 24.M Bauer*, M Blaickner, C Philippe, W Wadsak, M Hacker, M Zeitlinger, O Langer. Whole-body Distribution and Radiation Dosimetry of 11C-Elacridar and 11C-Tariquidar in Humans. J Nucl Med (2016) 57(8):1265-8 doi: 10.2967/jnumed.116.175182 IF 2017 7.439 25.M Bauer, K Römermann, R Karch, B Wulkersdorfer, J Stanek, C Philippe, A Maier-Salamon, H Haslacher, C Jungbauer, W Wadsak, W Jäger, W Löscher, M Hacker, M Zeitlinger, O Langer. A pilot

12/02/2021 European Medicines Agency Page 3/6 PET study to assess the functional interplay between ABCB1 and ABCG2 at the human blood-brain barrier. Clin Pharmacol Ther (2016) 100(2):131-41 doi: 10.1002/cpt.362. IF 2017 6.544 26.EK Masel, AS Berghoff, A Mladen, S Schur, B Maehr, M Kirchhoff, M Bauer, HH Watzke, M Amering. Psyche at the end of life: Psychiatric symptoms are prevalent in patients admitted to a palliative care unit. Palliative and Supportive Care (2015). 8:1-9 doi: 10.1017/S1478951515000899 IF 2017 1.494 27.M Bauer, R Karch, M Zeitlinger, C Philippe, K Römermann, J Stanek, A Maier-Salamon, W Wadsak, W Jäger, M Hacker, M Müller, O Langer. Approaching complete inhibition of P-glycoprotein at the human blood-brain barrier: an (R)-[11C]verapamil PET study. J Cereb Blood Flow Metab (2015) 35(5):743-6 doi: 10.1038/jcbfm.2015.19 IF 2017 6.045 28.M Bauer*, R Schwameis, T Scherzer, I Lang-ZwostaI, K Nishino, M Zeitlinger. A double-blind, randomized clinical study to determine the efficacy of 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. J Dermatolog Treat (2015) 26:1-22 doi: 10.3109/09546634.2014.992384 IF 2017 2.144 29.M Bauer, R Karch, M Zeitlinger, J Liu, MJ Koepp, M-C Asselin, SM Sisodiya, JA Hainfellner, W Wadsak, M Mitterhauser, M Müller, E Pataraia, O Langer. In vivo P-glycoprotein function before and after epilepsy . Neurology (2014) 83(15):1326-31 doi: 10.1212/WNL.0000000000000858 IF 2017 7.609 30.M Bauer, R Karch, M Zeitlinger, J Stanek, C Philippe, W Wadsak, M Mitterhauser, W Jäger, H Haslacher, M Müller, O Langer. Interaction of 11C-tariquidar and 11C-elacridar with P-glycoprotein and breast cancer resistance protein at the human blood-brain barrier. J Nucl Med (2013) 54(8):1181-7 doi: 10.2967/jnumed.112.118232 IF 2017 7.439 31.M Bauer, M Zeitlinger, D Todorut, M Böhmdorfer, M Müller, O Langer, W Jäger. Pharmaco-kinetics of single ascending doses of the P-glycoprotein inhibitor tariquidar in healthy sub-jects. Pharmacology (2013) 91(1-2):12-9 doi: 10.1159/000343243 IF 2017 1.538 32.M Feldmann, M-C Asselin, J Liu, S Wang, A McMahon, J Anton-Rodriguez, M Walker, M Symms, G Brown, R Hinz, J Matthews, M Bauer, O Langer, M Thom, T Jones, C Vollmar, JS Duncan, SM Sisodiya, MJ Koepp. P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol (2013) 12(8):777-85 doi: 10.1016/S1474-4422(13)70109-1 IF 2017 27.138 33.M Bauer, M Zeitlinger, R Karch, P Matzneller, J Stanek, W Jäger, M Böhmdorfer, W Wadsak, M Mitterhauser, JP Bankstahl, W Löscher, M Koepp, C Kuntner, M Müller, O Langer. Pgp-mediated interaction between (R)-[11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data. Clin Pharmacol Ther (2012) 91(2):227-33 doi: 10.1038/clpt.2011.217 IF 2017 6.544 34.DME van Assema, M Lubberink, M Bauer, WM van der Flier, RC Schuit, AD Windhorst, EFI Comans, NJ Hoetjes, N Tolboom, O Langer, M Müller, P Scheltens, AA Lammertsma, BNM van Berckel. Blood-brain barrier P-glycoprotein function in Alzheimers disease. Brain (2012) 135(Pt 1):181-9 doi: 10.1093/brain/awr298 IF 2017 10.840 35.J Müllauer, C Kuntner, M Bauer, JP Bankstahl, M Müller, RA Voskuyl, O Langer, S Syvänen. Pharmacokinetic-pharmacodynamic modeling of P-glycoprotein function at the rat and human blood-brain barrier studied with (R)-[11C]verapamil positron emission tomography. EJNMMI Research (2012) 2(1):58 doi: 10.1186/2191-219X-2-58 IF 2017 2.630 36.CC Wagner, M Simpson, M Zeitlinger, M Bauer, R Karch, A Abrahim, T Feurstein, M Schütz, K Kletter, M Müller, G Lappin, O Langer. A combined accelerator mass spectrometry-positron emission tomography human microdose study with 14C- and 11C-labelled verapamil. Clin Pharmacokin (2011) 50(2):111-20 doi: 10.2165/11537250-000000000-00000 IF 2017 4.464 37.M Bauer, R Karch, F Neumann, CC Wagner, K Kletter, M Müller, W Löscher, M Zeitlinger, O Langer. Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. J Cereb Blood Flow Metab (2010) 30(3):510-5 doi: 10.1038/jcbfm.2009.265 IF 2017 6.045 38.M Bauer, H Bliesath, C Leuratti, E Lackner, W Dieterle, M Müller, M Brunner. Disposition and metabolism of ralfinamide, a novel Na-, in healthy male volunteers. Pharmacology (2010) 86(5-6):297-305 doi: 10.1159/000321322 IF 2017 1.538 39.CC Wagner, M Bauer, R Karch, T Feurstein, S Kopp, P Chiba, K Kletter, W Löscher, M Mül-ler, M Zeitlinger, O Langer. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med (2009) 50(12):1954-61 doi: 10.2967/jnumed.109.063289 IF 2017 7.439

12/02/2021 European Medicines Agency Page 4/6 40.M Bauer, R Karch, F Neumann, A Abrahim, CC Wagner, K Kletter, M Müller, M Zeitlinger, O Langer. Age dependency of cerebral P-gp function measured with (R)-[11C]verapamil and PET. Eur J Clin Pharmacol (2009) 65(9):941-6 doi: 10.1007/s00228-009-0709-5 IF 2017 2.679 41.I Steiner, P Errhalt, K Kubesch, M Hubner, M Holy, M Bauer, M Müller, S Hinterberger, R Widmann, D Mascher, M Freissmuth, M Kneussl. Pulmonary pharmacokinetics and safety of nebulized duramycin in healthy male volunteers. Naunyn-Schmiedebergs Arch Pharmacol (2008) 378(3):323-33 doi: 10.1007/s00210-008-0293-8 IF 2017 2.238 42.C Kuntner, AL Kesner, M Bauer, R Kremslehner, T Wanek, M Mandler, R Karch, J Stanek, T Wolf, M Müller, O Langer. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol Imaing Biol (2008) 11(4):236-40 doi: 10.1007/s11307-009-0198-z IF 2017 3.608 43.A Abrahim, G Luurtsema, M Bauer, R Karch, M Lubberink, E Pataraia, C Joukhadar, K Klet-ter, AA Lammertsm, C Baumgartner, M Muller, O Langer. Peripheral metabolism of (R)-[11C]verapamil in epilepsy patients. Eur J Nucl Med Mol Imaging (2008) 35(1):116-23 IF 2017 7.704 44.U Berndt, C Stanetty, T Wanek, C Kuntner, J Stanek, M Berger, M Bauer, G Henriksen, HJ Wester, H Kvaternik,P Angelberger, C Noe. Synthesis of a [18F] fluorobenzothiazole as po-tential amyloid imaging agent. J Llabelled Ccompd Rad (2008) 51(3):137-45 doi: 10.1002/jlcr.1476 IF 2017 1.423, 45.O Langer, M Bauer, A Hammers, R Karch, E Pataraia, MJ Koepp, A Abrahim, G Luurtsema, M Brunner, R Sunder-Plassmann, F Zimprich, C Joukhadar, S Gentzsch, R Dudczak, K Kletter, M Müller, C Baumgartner. Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[11C]verapamil. Epilepsia (2007) 48(9):1774-84 IF 2017 5.067 46.M Bauer, O Langer, P Dal-Bianco, R Karch, M Brunner, A Abrahim, R Lanzenberger, A Hofmann,C Joukhadar, P Carminati, O Ghirardi, P Piovesan, G Forloni, ME Corrado, N Lods, R Dudczak, E Auff, K Kletter, M Muller. A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease. Clin Pharmacol Ther (2006) 80(3):216-27 IF 2017 6.544 Review Articles 47.A Weidenauer, M Bauer, U Sauerzopf, L Bartova, N Praschak-Rieder, H Sitte, S Kasper, M Willeit. Making Sense of: Sensitization in Schizophrenia. Int J Neuropsychopharmacol. (2016) 20(1):1-10 doi: 10.1093/ijnp/pyw081 IF 2017 3.981 48.B Wulkersdorfer, T Wanek, M Bauer, M Zeitlinger, M Müller, O Langer. Using positron emission tomography to study transporter-mediated drug-drug interactions in tissues. Clin Pharmacol Ther (2014) 96(2):206-13 doi: 10.1038/clpt.2014.70 IF 2017 6.544 49.M Bauer, N Praschak-Rieder, S Kasper, M Willeit. Is dopamine neurotransmission altered in prodromal schizophrenia? A review of the evidence. Curr Pharm Des 18(12):1568-79 (2012). IF 2017 2.757 50.M Bauer, CC Wagner, O Langer. Microdosing studies in humans: the role of positron emis-sion tomography. (2008) Drugs R D 9(2):73-81 IF not available 51.V Kulemann, M Bauer, W Graninger, C Joukhadar. Safety and potential of drug interactions of caspofungin and voriconazole in multimorbid patients. Pharmacology 75(4):165-78 (2005). IF 2017 1.538 Case Report 52.Z Litvan, M Bauer, S Kasper, R Frey. Electroconvulsive therapy with S- anesthesia for catatonia in coexisting depression and dementia. Int Psychogeriatr. (2017) 29(7):1223-5. doi: 10.1017/S104161021700014X. IF 2017 2.261 Letters to the Editor 53.M Bauer, M Zeitlinger, O Langer. Pharmacokinetic imaging with radiolabeled molecularly targeted anticancer drugs. J Nucl Med jnumed.119.236174 published ahead of print October 4, 2019 (10.2967/jnumed.119.236174) IF 2017 7.439 German Articles: 54.A Weidenauer, U Sauerzopf, L Bartova, M Bauer, N Praschak-Rieder, S Kasper, M Willeit. Sensibilisierung auf Amphetamine: Bedeutung fur die Schizophrenie- und Sucht-forschung. J Neurol Neurochir Psychiatr. (2018) 19(2):66-71 55.M Bauer. Antipsychotika, einige Fragen zu Nutzen und Risiko. Pharmainformation. (2016) 31/3 56.M Bauer. Rationale Verschreibung von Antidepressiva: Einige Kriterien Pharmainformation. (2015) 30/3

12/02/2021 European Medicines Agency Page 5/6 57.M Bauer. Ausgewählte Arzneimittelinteraktionen von Psychopharmaka. Mehrfach erschienen in den Medien der österreichischen Gebietskrankenkassen (im blickpunkt, top tipps etc.) 2015 58.M Bauer, R Gattringer, C Joukhadar. Fosfomycin im schwer erreichbaren Kompartiment. Antibiotika Monitor (2005) 21(1):3-8 Book Chapters 1.M Willeit, A Popovic, L Bartova, U Sauerzopf, M Bauer, N Praschak-Rieder. Neurotransmit-ter Transporters, Volume 118 of the series Neuromethods pp 203-220, 2016, Springer Pro-tocols. 2.M Bauer, O Langer. Tools in Clinical Pharmacology - Imaging Techniques in Clinical Pharmacology: Current Topics and Case Studies, 2nd Edition 2016, Springer, Editor: M. Müller. Projects Current projects: hepatic drug transport ABCB1 in epilepsy In vivo imaging ABC and OATP transporter activity and DDIs involving transporters in different organs Imaging Dopamine function in Schizophrenia and models of Schizophrenia Sources of funding (PI and Co-investigator) 2020 - 2023 ANR, France and FWF, Austria "EPIFLUX" 261.952,32 2008 - 2015FWF, AustriaSpecial Research Programme F35 "Transmembrane Transporters in Health and Disease"683.308 2011 - 2015FWF, AustriaAtypical antipsychotics and soft tissue gene expression158.180 2011 - 2015FWF, AustriaCerebral dopamine release in sensitization and first episode schizophrenia249.847 2008 - 2012FP7, EU"Euripides"184.720

Memberships Austrian Pharmacological Society Honors: 2018 May Höfer Preis for the best publication in Nuclear Medicine: 2nd 2015 May Höfer Preis for the best publication in Nuclear Medicine: 2nd 2015 Mar Researcher of the Month Medical University of Vienna 2015 Mar vfwf Habilitation Award 2014 Nov Herbert-Reisner Award, Austrian Society of Epilepsy 2010 Sep Poster Presentation Award, APHAR Member of the Ethics Committe of the Medical University of Vienna and the Ethics Committe of the University of Vienna. Other Relevant Information

12/02/2021 European Medicines Agency Page 6/6